Stock itci.

Intra-Cellular Therapies, Inc. (ITCI) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 62.84 +1.47 (+2.40%) At close: 04:00PM EST. 60.44 -2.40 (-3.82%) After hours:...Intra-Cellular Therapies (ITCI) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow SA Transcripts Fri, Jun. 04, 2021 Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on ...Nov 27, 2023 · A high-level overview of Intra-Cellular Therapies, Inc. (ITCI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Earnings announcement* for ITCI: Nov 08, 2022. Intra-Cellular Therapies Inc. is estimated to report earnings on 11/08/2022. The upcoming earnings date is derived from an algorithm based on a ...Find the latest Institutional Holdings data for Intra-Cellular Therapies Inc. Common Stock (ITCI) at Nasdaq.com.

To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios. Stocks with a Value Score from 81-100 are considered deep value, those with a score between 61-80 are value and so on. Intra-Cellular Therapies Inc has a Value Score of 5, which is Ultra Expensive.Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online. The net and percent change in the quote ...Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($1.68) to ($0.80) per share. Intra-Cellular Therapies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More.

8 analysts have issued 12-month price targets for Intra-Cellular Therapies' stock. Their ITCI share price targets range from $62.00 to $101.00. On average, they …NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the Company’s Virtual Event featuring highlights of its development programs being held on Wednesday, …

According to . 5 Wall Street analysts that have issued a 1 year ITCI price target, the average ITCI price target is $78.20, with the highest ITCI stock price forecast at $101.00 and the lowest ITCI stock price forecast at $62.00.Read why ITCI stock is a Hold. Intra-Cellular Therapeutics develops small molecule drugs targeting the CNS for neuropsychiatric and neurological disorders. Read why ITCI stock is a Hold.8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | December 30, 2022On November 2, 2023, Intra-Cellular Therapies Inc (ITCI) stock had a median target price of $76.00, according to 13 analysts offering 12-month price forecasts. The high estimate for the stock was $100.00, while the low estimate was $59.00. The consensus among 14 investment analysts was to buy stock in Intra-Cellular Therapies Inc.NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the completion of its previously announced underwritten public offering of 9,523,810 shares of its common …

Intra-Cellular Therapies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ITCI updated stock price target summary.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) reported Q3 2023 total revenues of $126.2 million, a 75% increase compared to the same period in 2022. CAPLYTA Q3 2023 net product sales were $125.8 million, representing a 75% increase. CAPLYTA total prescriptions increased 71% in Q3 2023.

ITCI stock shot up to approximately $55 per share after the success of study 403. There is some overhead supply to work through to reach new all-time highs and continued strong sales momentum and ...Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...Latest Intra-Cellular Therapies News: View ITCI news and discuss market sentiment with the investor community on Public.com.The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $78.67. ITCI has been the topic of a number of research analyst reports. Needham & Company LLC lifted their target price on Intra-Cellular Therapies from $71.00 to $72.00 and gave the stock a “buy” rating in a report on Friday ...ITCI is a biopharmaceutical company that develops novel drugs for treating neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system. On August 22, 2022, The Goldman Sachs Group Inc. ( GS ) downgraded ITCI from a “buy” rating to a “neutral” rating.Intra-Cellular Therapies Inc. Common Stock (ITCI) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Mar 28, 2023 · The stock is down more than 12% over the past 12 months but up more than 2% so far in 2023. ... (ITCI) Q3 2021 Earnings Call Transcript. Why Intra-Cellular Therapies Was Weak This Week.

Intra-Cellular Therapies ( NASDAQ: ITCI) stock traded much higher recently after it had obtained FDA approval for its drug CAPLYTA (lumateperone) for the treatment of adults with bipolar ...Real time Intra-Cellular Therapies (ITCI) stock price quote, stock graph, news & analysis.A high-level overview of Intra-Cellular Therapies, Inc. (ITCI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …NasdaqGS:ITCI Insider Trading Volume December 3rd 2023. For those who like to find winning investments this free list of growing companies with recent insider …Nov 20, 2023 · Shares of ITCI responded in kind, rallying 16% in the subsequent trading session and ultimately 40% higher to an all-time high of $67.05 in June 2023, suggesting peak sales of $1.75 billion to $2. ... ITCI The Nasdaq Global Select Market ... Common stock, $ 0.0001 par value: 175,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, ...

NasdaqGS:ITCI Insider Trading Volume December 3rd 2023. For those who like to find winning investments this free list of growing companies with recent insider …

TipRanks | Stock Market Research, News and Analyst Forecasts ... Intra-Cellular Therapies Inc. 430 East 29th Street. Suite 900. New York, New York 10016. Phone 1 464 440-9333. Industry Pharmaceuticals. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023 ...In terms of how INTRA-CELLULAR THERAPIES INC fares relative to Pharmaceutical Products stocks, note that its average analyst price target is higher than 3826.61% of that group. ITCI has a greater number of analysts covering the stock than 3418.44% of stocks in the mid market cap category.The stock of Intra-Cellular Therapies Inc (ITCI) has gone up by 5.10% for the week, with a -1.20% drop in the past month and a -13.62% drop in the past quarter. The volatility ratio for the week is 5.20%, and the volatility levels for the past 30 days are 3.88% for ITCI. The simple moving average foIn terms of how INTRA-CELLULAR THERAPIES INC fares relative to Pharmaceutical Products stocks, note that its average analyst price target is higher than 3826.61% of that group. ITCI has a greater number of analysts covering the stock than 3418.44% of stocks in the mid market cap category.IntraCellular Therapies (ITCI) (Delayed Data from NSDQ) $61.37 USD +1.94 (3.26%) Updated Nov 30, 2023 04:00 PM ET After-Market: $61.37 0.00 (0.00%) 4:48 PM …Track Intra-Cellular Therapies Inc (ITCI) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsredhotace. 2. 7/7/2023 11:45:09 PM. 447. Needham raises PT to $73 From $70, Keeps Buy Rating. GN. redhotace.Earnings announcement* for ITCI: Nov 08, 2022. Intra-Cellular Therapies Inc. is estimated to report earnings on 11/08/2022. The upcoming earnings date is derived from an algorithm based on a ...The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $78.67. ITCI has been the topic of a number of research analyst reports. Needham & Company LLC lifted their target price on Intra-Cellular Therapies from $71.00 to $72.00 and gave the stock a “buy” rating in a report on Friday ...

000156751412-312023Q3false13600015675142023-01-012023-09-3000015675142023-10-31xbrli:shares00015675142023-09 …

Nov 30, 2023 · 8 Wall Street analysts have issued 1-year target prices for Intra-Cellular Therapies' stock. Their ITCI share price targets range from $62.00 to $101.00. On average, they predict the company's stock price to reach $78.67 in the next year. This suggests a possible upside of 28.2% from the stock's current price.

ITCI Stock Overview. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Disruption hit MTR services to Hong Kong’s airport for about an hour on Sunday, because of a fault with the baggage handling system at Airport station. Services were back to normal by 1.25pm. The total journey time on the Airport Express from Hong Kong station to AsiaWorld-Expo station was extended by five to 10 minutes, according to …Insider Sell: Sharon Mates Sells 100,000 Shares of Intra-Cellular Therapies Inc. On September 19, 2023, Sharon Mates, Chairman, President & CEO of Intra-Cellular Therapies Inc (NASDAQ:ITCI), sold ... The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...See the latest Intra-Cellular Therapies Inc stock price (NASDAQ:ITCI), related news, valuation, dividends and more to help you make your investing decisions.ITCI has a Quality Grade of D, ranking ahead of 18.25% of graded US stocks. ITCI's asset turnover comes in at 0.08 -- ranking 278th of 682 Pharmaceutical Products stocks. …Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) reported Q3 2023 total revenues of $126.2 million, a 75% increase compared to the same period in 2022. CAPLYTA Q3 2023 net product sales were $125.8 million, representing a 75% increase. CAPLYTA total prescriptions increased 71% in Q3 2023.Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500. Click here - the ITCI analysis is free ». Price. 2021 ...

Intra-Cellular Therapies (ITCI) Jefferies analyst Andrew Tsai maintained a Buy rating on Intra-Cellular Therapies on October 6 and set a price target of $95.00 . The company’s shares closed last ...Biotech Alert: Searches spiking for these stocks today May 5, 2023TipRanks. Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Phibro Animal Health (PAHC) and ...The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 33% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong …JuSun/iStock via Getty Images. Intra-Cellular Therapies ( ITCI +10.0%) has bounced back from a one-month low as several Wall Street analysts pointed to the strong performance of the company’s ...Instagram:https://instagram. short term health plans texasintegra loans reviewsnyse earnis realtymogul legit Stock Price Statistics. The stock price has increased by +13.77% in the last 52 weeks. The beta is 1.04, so ITCI's price volatility has been similar to the market average.Intra-Cellular Therapies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ITCI updated stock price target summary. vanguard high dividendluxx etf Since its IPO on the Shenzhen stock exchange, its share price has gone up every day by the exact same amount. Baofeng Technologies is China’s best performing stock this year. Since its IPO on the Shenzhen stock exchange, its share price has... intel corporation dividend The stock price for . Intra-Cellular Therapies (NASDAQ: ITCI) is $59.42 last updated November 24, 2023 at 6:00 PM UTC. Q Does Intra-Cellular Therapies (ITCI) pay a dividend? by Zacks Equity Research Published on November 07,2023. The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric ...